Chemically Precise Glycoengineering Improves Human Insulin

ACS Chem Biol. 2018 Jan 19;13(1):73-81. doi: 10.1021/acschembio.7b00794. Epub 2017 Dec 1.

Abstract

Diabetes is a leading cause of death worldwide and results in over 3 million annual deaths. While insulin manages the disease well, many patients fail to comply with injection schedules, and despite significant investment, a more convenient oral formulation of insulin is still unavailable. Studies suggest that glycosylation may stabilize peptides for oral delivery, but the demanding production of homogeneously glycosylated peptides has hampered transition into the clinic. We report here the first total synthesis of homogeneously glycosylated insulin. After characterizing a series of insulin glycoforms with systematically varied O-glycosylation sites and structures, we demonstrate that O-mannosylation of insulin B-chain Thr27 reduces the peptide's susceptibility to proteases and self-association, both critical properties for oral dosing, while maintaining full activity. This work illustrates the promise of glycosylation as a general mechanism for regulating peptide activity and expanding its therapeutic use.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cell Line
  • Drug Design
  • Glucose Transporter Type 4 / metabolism
  • Humans
  • Insulin / analogs & derivatives*
  • Insulin / chemistry
  • Insulin / metabolism
  • Insulin / pharmacology
  • Mice
  • Protein Engineering / methods*
  • Structure-Activity Relationship
  • Threonine / chemistry

Substances

  • Glucose Transporter Type 4
  • Insulin
  • Slc2a4 protein, mouse
  • insulin, glycosylated
  • Threonine